Saxenda for teens: what the pediatric obesity data actually shows

What did @dra.anaveronica actually say?

Honestly? Not much that we can work with. The transcript is nearly incoherent, offering fragments like "I have seen a lot of news" and vague references to making "a better world" alongside mentions of links in a description. The video is tagged with #saxenda and #liraglutida and appears to be a reply about adolescent use of Saxenda, but the spoken content doesn't deliver a clear medical claim we can pin down. The caption context, replying to a user about Saxenda use in adolescentes, is doing more communicative work than the transcript itself. We're fact-checking the implied topic, liraglutide (Saxenda) in adolescents, because that's clearly what the video is about, even if the audio didn't cooperate with us.

Does the science back this up?

On the core topic the video gestures toward, the pediatric use of liraglutide, the science is real and worth knowing. The FDA approved Saxenda (liraglutide 3 mg) for adolescents aged 12 and older with obesity in December 2020, making it one of the few weight-management medications with a formal pediatric indication. A randomized controlled trial by Kelly et al. (2020, New England Journal of Medicine) found that liraglutide 3 mg daily, combined with lifestyle intervention, produced significantly greater weight reduction than placebo in adolescents 12-17 with obesity. The trial showed a mean reduction in BMI of about 4.5% more than placebo over 56 weeks. That's a meaningful signal, not a dramatic transformation, but statistically significant and clinically relevant for a population with limited pharmacological options. Adverse effects, mainly nausea and vomiting, were more common in the treatment group, which is consistent with the adult data.

What did they get wrong (or right)?

We can't fairly say @dra.anaveronica got the science wrong, because she didn't clearly state any science. What she got right, at least implicitly, is that Saxenda in adolescents is a legitimate clinical conversation worth having. The hashtag framing around bariatric medicine and clinical weight control suggests a medical professional context, which is appropriate given that liraglutide in teens requires a prescription, medical supervision, and is not a casual intervention. What concerns us is the vagueness. Videos that promise information via description links without delivering substantive spoken content are a low-quality format for medical education. If there's real clinical nuance here, it belongs in the video, not buried in a link that most viewers won't click. This is a missed opportunity, not a misinformation event, but that doesn't make it useful content.

What should you actually know?

If you or a family member are considering Saxenda for an adolescent, here's what the evidence actually says. Liraglutide 3 mg is FDA-approved for teens 12 and older with a BMI at or above the 95th percentile. It works by mimicking GLP-1, slowing gastric emptying and reducing appetite. The Kelly et al. 2020 NEJM trial is the primary evidence base for this population. It's not a cure for obesity, and weight typically returns after stopping the medication. The American Academy of Pediatrics issued updated guidelines in 2023 recommending early, active treatment of childhood obesity, including pharmacotherapy when appropriate, a shift from the older wait-and-see approach. Saxenda is also not interchangeable with compounded liraglutide products, which have not undergone the same regulatory review. Any adolescent use must be supervised by a qualified clinician who can monitor for side effects including pancreatitis risk, heart rate changes, and gastrointestinal symptoms.